Locations:
SearchAdvertisement
Early intervention helps prevent chronic lymphedema
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management
Approach could help clinicians identify patients at an increased risk of progression who could benefit from more aggressive treatment
Polygenic risk score could help predict who will develop this aggressive breast cancer
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Family history may eclipse sun exposure in some cases
Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’
Extent of baseline burden impacts progression-free and overall survival
Further study warranted to better understand the clinical implications of these findings
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
Advertisement
Advertisement